|
1
|
Van Zandwijk N, Clarke C, Henderson D,
Musk AW, Fong K, Nowak A, Loneragan R, McCaughan B, Boyer M, Feigen
M, et al: Guidelines for the diagnosis and treatment of malignant
pleural mesothelioma. J Thorac Dis. 5:E254–E307. 2013.PubMed/NCBI
|
|
2
|
Hui S, Guo-Qi Z, Xiao-Zhong G, Chun-Rong
L, Yu-Fei L and Dong-Liang-Y: IMP3 as a prognostic biomarker in
patients with malignant peritoneal mesothelioma. Hum Pathol.
81:138–147. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alexander HR, Bartlett DL, Pingpank JF,
Libutti SK, Royal R, Hughes MS, Holtzman M, Hanna N, Turner K,
Beresneva T and Zhu Y: Treatment factors associated with long-term
survival after cytoreductive surgery and regional chemotherapy for
patients with malignant peritoneal mesothelioma. Surgery.
153:779–786. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gerdes J, Li L, Schlueter C, Duchrow M,
Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E and Flad HD:
Immunobiochemical and molecular biologic characterization of the
cell proliferation-associated nuclear antigen that is defined by
monoclonal antibody Ki-67. Am J Pathol. 138:867–873.
1991.PubMed/NCBI
|
|
5
|
Cuzick J, Dowsett M, Pineda S, Wale C,
Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, et al:
Prognostic value of a combined estrogen receptor, progesterone
receptor, Ki-67, and human epidermal growth factor receptor 2
immunohistochemical score and comparison with the genomic health
recurrence score in early breast cancer. J Clin Oncol.
29:4273–4278. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang J, Ramnath N, Moysich KB, Asch HL,
Swede H, Alrawi SJ, Huberman J, Geradts J, Brooks JS and Tan D:
Prognostic significance of MCM2, Ki-67 and gelsolin in non-small
cell lung cancer. BMC Cancer. 6:2032006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zellweger T, Günther S, Zlobec I, Savic S,
Sauter G, Moch H, Mattarelli G, Eichenberger T, Curschellas E,
Rüfenacht H, et al: Tumour growth fraction measured by
immunohistochemical staining of Ki67 is an independent prognostic
factor in preoperative prostate biopsies with small-volume or
low-grade prostate cancer. Int J Cancer. 124:2116–2123. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ghanim B, Klikovits T, Hoda MA, Lang G,
Szirtes I, Setinek U, Rozsas A, Renyi-Vamos F, Laszlo V, Grusch M,
et al: Ki67 index is an independent prognostic factor in
epithelioid but not in non-epithelioid malignant pleural
mesothelioma: A multicenter study. Br J Cancer. 112:783–792. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang G, Zhang L, Zhu Q, Bai D, Zhang C
and Wang X: CD146 promotes metastasis and predicts poor prognosis
of hepatocellularcarcinoma. J Exp Clin Cancer Res. 35:382016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lei X, Guan CW, Song Y and Wang H: The
multifaceted role of CD146/MCAM in the promotion of melanoma
progression. Cancer Cell Int. 15:32015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang W, Yang ZL, Liu JQ, Jiang S and Miao
XY: Identification of CD146 expression, angiogenesis, and
lymphangiogenesis as progression, metastasis and poor-prognosis
related markers for gallbladder adenocarcinoma. Tumour Biol.
33:173–182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sato A, Torii I, Okamura Y, Yamamoto T,
Nishigami T, Kataoka TR, Song M, Hasegawa S, Nakano T, Kamei T and
Tsujimura T: Immunocytochemistry of CD146 is useful to discriminate
between malignant pleural mesothelioma and reactive mesothelium.
Mod Pathol. 23:1458–1466. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Okazaki Y, Nagai H, Chew SH, Li J,
Funahashi S, Tsujimura T and Toyokuni S: CD146 and insulin-like
growth factor 2 mRNA-binding protein 3 predict prognosis of
asbestos-induced rat mesothelioma. Cancer Sci. 104:989–995. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goričar K, Kovač V, Franko A, Dodič-Fikfak
M and Dolžan V: Serum surviving levels and outcome of chemotherapy
in patients with maligna-nt mesothelioma. Dis Markers.
2015:3167392015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: Key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 15:5000–5005.
2008. View Article : Google Scholar
|
|
16
|
Arellano-Orden E, Romero-Romero B,
Sánchez-López V, Martín-Juan J, Rodríguez-Panadero F and
Otero-Candelera R: Survivin is a negative prognostic factor in
malignant pleural effusion. Eur J Clin Invest. 48:102018.
View Article : Google Scholar
|
|
17
|
Contis J, Lykoudis PM, Goula K, Karandrea
D and Kondi-Pafiti A: Survivinn expression as an independent
predictor of overall survival in pancreatic adenocarcinoma. J
Cancer Res Ther. 14 (Suppl):S719–S723. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gordon GJ, Mani M, Mukhopadhyay L, Dong L,
Edenfield HR, Glickman JN, Yeap BY, Sugarbaker DJ and Bueno R:
Expression patterns of inhibitor of apoptosis proteins in malignant
pleural mesothelioma. J Pathol. 211:447–454. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Husain AN, Colby T, Ordonez N, Krausz T,
Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac
LR, et al: Guidelines for pathologic diagnosis of malignant
mesothelioma: 2012 update of the consensus statement from the
international mesothelioma interest group. Arch Pathol Lab Med.
137:647–667. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yan TD, Deraco M, Elias D, Glehen O,
Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH, et
al: A novel tumor-node-metastasis (TNM) staging system of diffuse
malignant peritoneal mesothelioma using outcome analysis of a
multi-institutional database. Cancer. 117:1855–1863. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vigneswaran WT, Kircheva DY,
Ananthanarayanan V, Watson S, Arif Q, Celauro AD, Kindler HL and
Husain AN: Amount of epithelioid differentiation is a predictor of
survival in malignant pleural mesothelioma. Ann Thorac Surg.
103:962–966. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yin W, Zheng G, Yang K, Song H and Liang
Y: Analysis of prognostic factors of patients with malignant
peritoneal mesothelioma. World J Surg Oncol. 16:442018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hommell-Fontaine J, Isaac S, Passot G,
Decullier E, Traverse-Glehen A, Cotte E, You B, Mohamed F, Gilly
FN, Glehen O and Berger F: Malignant peritoneal mesothelioma
treated by cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy: Is GLUT1 expression a major prognostic factor? A
preliminary study. Ann Surg Oncol. 20:3892–3898. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Verma V, Sleightholm RL, Rusthoven CG,
Koshy M, Sher DJ, Grover S and Simone CB II: Malignant peritoneal
mesothelioma: National practice patterns, outcomes, and predictors
of survival. Ann Surg Oncol. 25:2018–2026. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shavelle R, Vavra-Musser K, Lee J and
Brooks J: Life expectancy in pleural and peritoneal mesothelioma.
Lung Cancer Int. 2017:27825902017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leinwand JC, Taub RN, Chabot JA and Kluger
MD: Two-Stage cytoreductive surgery and intraperitoneal
chemotherapy for diffuse malignant peritoneal mesothelioma:
Predictors of overall survival in an intention-to-treat series. Ann
Surg Oncol Dec. 12:102019.
|
|
27
|
Magge D, Zenati MS, Austin F, Mavanur A,
Sathaiah M, Ramalingam L, Jones H, Zureikat AH, Holtzman M, Ahrendt
S, et al: Malignant peritoneal mesothelioma: Prognostic factors and
oncologic outcome analysis. Ann Surg Oncol. 21:1159–1165. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takamori S, Toyokawa G, Shimokawa M,
Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F,
Seto T, et al: The c-reactive protein/albumin ratio is a novel
significant prognostic factor in patients with malignant pleural
mesothelioma: A retrospective multi-institutional study. Ann Surg
Oncol. 25:1555–1563. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Helm JH, Miura JT, Glenn JA, Marcus RK,
Larrieux G, Jayakrishnan TT, Donahue AE, Gamblin TC, Turaga KK and
Johnston FM: Cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy for malignant peritoneal mesothelioma: A systematic
review and meta-analysis. Ann Surg Oncol. 22:1686–1693. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Levý M, Boublíková L, Büchler T and Šimša
J: Treatment of malignant peritoneal mesothelioma. Klin Onkol.
32:333–337. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Feldman AL, Libutti SK, Pingpank JF,
Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ,
Kleiner DE and Alexander HR: Analysis of factors associated with
outcome in patients with malignant peritoneal mesothelioma
undergoing surgical debulking and intraperitoneal chemotherapy. J
Clin Oncol. 21:4560–4567. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pillai K, Pourgholami MH, Chua TC and
Morris DL: Ki67-BCL2 index in prognosis of malignant peritoneal
mesothelioma. Am J Cancer Res. 3:411–423. 2013.PubMed/NCBI
|
|
33
|
Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y,
Feng J, Yang D, Fu L and Yan X: CD146, an epithelial-mesenchymal
transition inducer, is associated with triple-negative breast
cancer. Proc Natl Acad Sci USA. 109:1127–1132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu Q, Zhang B, Zhao X, Zhang Y, Liu Y and
Yan X: Blockade of adhesion molecule CD146 causes pregnancy failure
in mice. J Cell Physiol. 215:621–626. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bidlingmaier S, He J, Wang Y, An F, Feng
J, Barbone D, Gao D, Franc B, Broaddus VC and Liu B: Identification
of MCAM/CD146 as the target antigen of a human monoclonal antibody
that recognizes both epithelioid and sarcomatoid types of
mesothelioma. Cancer Res. 69:1570–1577. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nigam J, Chandra A, Kazmi HR, Singh A,
Gupta V, Parmar D and Srivastava MK: Expression of serum survivin
protein in diagnosis and prognosis of gallbladder cancer: A
comparative study. Med Oncol. 31:1672014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ren YQ, Zhang HY, Su T, Wang XH and Zhang
L: Clinical significance of serum survivin in patients with
pancreatic ductal adenocarcinoma. Eur Rev Med Pharmacol Sci.
18:3063–3068. 2014.PubMed/NCBI
|
|
38
|
Meerang M, Bérard K, Friess M, Bitanihirwe
BK, Soltermann A, Vrugt B, Felley-Bosco E, Bueno R, Richards WG,
Seifert B, et al: Low merlin expression and high survivin labeling
index are indicators for poor prognosis in patients with malignant
pleural mesothelioma. Mol Oncol. 10:1255–1265. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hmeljak J, Erčulj N, Dolžan V, Kern I and
Cör A: BIRC5 promoter SNPs do not affect nuclear survivin
expression and survival of malignant pleural mesothelioma patients.
J Cancer Res Clin Oncol. 137:1641–1651. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kleinberg L, Lie AK, Flørenes VA, Nesland
JM and Davidson B: Expression of inhibitor-of-apoptosis protein
family members in malignant mesothelioma. Hum Pathol. 38:986–994.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
De Cesare M, Cominetti D, Doldi V,
Lopergolo A, Deraco M, Gandellini P, Friedlander S, Landesma Y,
Kauffman MG, Shacham S, et al: Anti-Tumor activity of selective
inhibitors of XPO1/CRM1-mediated nuclear export in diffuse
malignant peritoneal mesothelioma: The role of survivin.
Oncotarget. 6:13119–13132. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zaffaroni N, Costa A, Pennati M, De Marco
C, Affini E, Madeo M, Erdas R, Cabras A, Kusamura S and Baratti D:
Survivin is highly expressed and promotes cell survival in
malignant peritoneal mesothelioma. Cell Oncol. 29:453–466.
2007.PubMed/NCBI
|
|
43
|
Bitanihirwe BK, Meerang M, Friess M,
Soltermann A, Frischknecht L, Thies S, Felley-Bosco E, Tsao MS,
Allo G, de Perrot M, et al: PI3K/mTOR signaling in mesothelioma
patients treated with induction chemotherapy followed by
extrapleural pneumonectomy. J Thorac Oncol. 9:239–247. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hmeljak J, Erčulj N, Dolžan V, Pižem J,
Kern I, Kovač V, Cemažar M and Cör A: Is survivin expression
prognostic or predictive in malignant pleural mesothelioma.
Virchows Arch. 462:315–321. 2013. View Article : Google Scholar : PubMed/NCBI
|
